Development and Validation of LC-UV for Simultaneous Estimation of Rosiglitazone and Glimepride in Human Plasma

A simple, sensitive and specific liquid chromatographic method with UV detection (228 nm) was developed for the simultaneous estimation of rosiglitazone and glimepride in human plasma. Rosiglitazone and glimepride were extracted from plasma using liquid–liquid extraction. Separation was achieved with an RP C₁₈ Column using a mixture of phosphate buffer (50 mM) with octane sulfonic acid (10 mM), methanol and acetonitrile as a mobile phase (55:10:35, v/v). pH was adjusted to 7.0. Amlodipine was used as an internal standard (IS). LOD of the method was found to be 20 ng mL^?1 for both drugs. Results were linear over the studied range 40.994–2007.556 ng mL^?1 for rosiglitazone (r ² ≥ 0.99) and 41.066–2094.84 ng mL^?1 for glimepride( r ² ≥ 0.99). The method was found to be simple, selective, precise and reproducible for the estimation of both drugs from spiked human plasma.     

Development and Validation of a Novel Gradient LC Method for Simultaneous Determination of Isoniazid and Acetylisoniazid in Human Plasma

The goal of this study was to develop and validate a new gradient high-performance liquid chromatography method for the simultaneous determination of isoniazid (INH) and acetylisoniazid (Ac-INH) in human plasma samples. A C18 reversed-phase column was employed for separation followed by UV detection at 266 nm. The calibration involved the use of five concentration levels ranging from 1 to 20 μg mL^?1 for both analytes. The developed method was validated using ICH guidelines. The calibration curve was found to be linear with correlation coefficient values (r ²) above 0.9991 and the highest RSD% values for intra-day assays were found to be 6.34 and 2.57% for INH and Ac-INH, respectively. The highest RSD% values for inter-day assays were 9.31 and 10.17% for INH and Ac-INH, respectively. LOD was calculated to be 0.1 and 0.15 μg mL^?1 for INH and Ac-INH, respectively. LOQ was calculated to be 0.33 and 0.5 μg mL^?1 for INH and Ac-INH, respectively.     

LC-MS-MS Development and Validation for Quantitative Determination of Methoxsalen in Human Plasma

A rapid, sensitive and specific method for quantification of methoxsalen in human plasma using metaxalone as the internal standard is presented. An Applied Biosystems Sciex API 3200 triple quadrupole mass spectrometer in multiple reaction monitoring mode, using TurboIonSpray in the positive ion mode was used. Simple solid phase extraction was followed by C18 reverse phase chromatography and tandem mass spectrometry using metaxalone as the internal standard. The mean recovery for methoxsalen was 90.0% with a lower limit of quantification of 1.0 ng mL^?1. This validated assay method makes use of the sensitivity and selectivity of tandem mass spectrometry detection to allow for a more rapid and selective method for the determination of methoxsalen in human plasma.     

Development and Validation of an LC-MS/MS Method for Simultaneous Determination of Short Peptide-Based Drugs in Human Blood Plasma

A novel HPLC-ESI-MS/MS method for simultaneous gonadotropin-releasing hormone (GnRH) analogs and somatostatin analog quantitation was developed and validated. The developed method was successfully applied to pharmacokinetic studies. The sample preparation process included solid-phase extraction (SPE). Effective chromatographic separation of the analytes and internal standard (dalargin) was achieved with a C18 column, using a gradient elution with two mobile phases: 0.1% v/v formic acid (aqueous solution) and 0.1% v/v formic acid (acetonitrile solution). The linearity of the method was demonstrated within a concentration range of 0.5–20 ng/mL, with correlation coefficients between 0.998–0.999 for goserelin, buserelin, triptorelin, and octreotide, respectively. The relative standard deviation (RSD, %) values for method accuracy and precision did not exceed 20% at the lower level of quantitation (LLOQ) or 15% at other concentration levels.     

Voltammetric Determination of Rosiglitazone in Pharmaceutical Preparations and Human Plasma

Abstract

The voltammetric behavior of rosiglitazone was studied using direct current (DC_t), differential pulse (DPP), and alternating current (AC_t) polarography. The drug manifests cathodic waves over a pH range of 2–11.2. In Britton‐Robinson buffer (BRb; pH 4), the diffusion current–concentration relationship was found to be rectilinear over a range of 4–24 µg · mL^?1 and 0.1–16 µg · mL^?1 using DC_t and DPP modes, respectively, with minimum limits of detection (LOD) of 0.15 µg · mL^?1 and 0.07 µg · mL^?1 using the DC_t and DDP modes, respectively. The diffusion‐current constant (I _d) was 6.63±0.03 (n=5). The proposed method was successfully applied to the determination of the studied compound both in pure form and in formulations. The mean percentage recoveries in tablets were 100.09±1.18 and 100.85±0.88 (n=5) using DC_t and DPP modes, respectively. Furthermore, the proposed method, adopting the DPP mode, was applied to the determination of rosiglitazone in spiked human plasma and the obtained mean percentage recoveries were 99.14±3.29 (n=4).     

Development and Validation of an Improved LC Method for the Simultaneous Determination of Pirfenidone and Its Carboxylic Acid Metabolite in Human Plasma

A sensitive and specific assay based on liquid chromatography with ultraviolet detection was developed for the simultaneous determination of pirfenidone (PFD), a novel antifibrotic agent, and its carboxylic acid metabolite in human plasma. The carboxylic acid metabolite was further identified by mass spectrometric analysis. PFD, its carboxylic acid metabolite and the internal standard methyl-p-aminobenzoate were extracted from plasma by a simple one-step liquid-liquid extraction with ethyl acetate and subsequently separated on a Zorbax SB-C18 column with a mobile phase of trifluoroacetic acid–triethylamine–acetonitrile–water (0.1:0.15:28:71.75, v/v/v/v) and monitored at 314 nm. Extraction recovery was over 70% in plasma. The calibration curves were linear over the concentration range of 0.05–25 μg mL^?1. The limit of detection (LOD) and lower limit of quantitation (LLOQ) in human plasma were 10 and 50 ng mL^?1, respectively. Intra- and inter-assay precision of the method were within 8.6%. The accuracy as expressed by the bias ranged between ?4.5 and 4.0%. The method was successfully applied to determine pharmacokinetic parameters of PFD and its carboxylic acid metabolite after a single oral dose of 200 mg of PFD in healthy volunteers.     

Method Development and Validation of a Rapid Determination of Ropinirole in Tablets by LC-UV

A reversed-phase high-performance liquid chromatographic (HPLC) method with UV detection was developed and validated for the determination of ropinirole (ROP) in tablets. The assay utilized UV detection at 250 nm and a Luna CN column (250 × 4.6 mm I.D, 5 μm). The mobile phases were comprised of acetonitrile: 10 mM nitric acid (pH 3.0) (75:25, v/v). Validation experiments were performed to demonstrate linearity, accuracy, precision, limit of quantitation (LOQ), limit of detection (LOD), and robustness. The method was linear over the concentration range of 0.5–10.0 μg mL⁻¹. The method showed good recoveries (99.75–100.20%) and the relative standard deviations of intra and inter-day assays were 0.38–1.69 and 0.45–1.95%, respectively. The method can be used for quality control assay of ropinirole.     

Development and Validation of a Liquid Chromatographic Method for Determination of Efavirenz in Human Plasma

A simple, rapid, and sensitive high-performance liquid chromatographic method for estimation of efavirenz in human plasma has been developed and validated. Chromatography was performed with C₁₈ analytical column and 50:50 acetonitrile–phosphate buffer (pH 3.5) as mobile phase. Compounds were monitored by UV detection at 247 nm. The retention time for efavirenz was 6.45 min and that for the internal standard, nelfinavir, was 2.042 min. Response was a linear over the concentration range of 0.1 μg–10 μg mL⁻¹ in human plasma. The method was simple, specific, precise and accurate and was useful for bioequivalence and pharmacokinetic studies of efavirenz.     

Development and Validation of a Densitometric HPTLC Method for Quantitative Analysis of Levofloxacin in Human Plasma

JPC – Journal of Planar Chromatography – Modern TLC -     

Development and Validation of LC-ESI-MS/MS Method for the Determination of Alfuzosin in Human Plasma

Journal of Analytical Chemistry - A new liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) method has been developed and validated for alfuzosin quantification in...     

Development and Validation an LC Method for the Determination of Bendroflumethiazide in Human Plasma and its Pharmacokinetics

A simple, rapid, sensitive high performance liquid chromatography method with fluorescent detection was developed and validated for the determination of bendroflumethiazide in human plasma. Extraction from the plasma was by liquid-liquid extraction using ethyl acetate. Mosapride citrate was used as the internal standard. The chromatographic separation was performed on reverse phase LiChrosphere C18 column with mobile phase comprising of acetonitrile and phosphate buffer (38:62 v/v). The assay precision ranged from 0.9–12.5 and accuracy between 96.8–108.8%, revealing that the method has good reproducibility over the concentration range of 0.98–100.16 ng mL⁻¹. The validated method has been applied to analyze the bendroflumethiazide concentrations for application in pharmacokinetic, bioavailability or bioequivalence studies.     

Development and Validation of a Reliable UHPLC-MS/MS Method for Simultaneous Quantification of Macrocyclic Lactones in Bovine Plasma

A fast, accurate and reliable ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) method was developed for simultaneous quantification of ivermectin (IVER), doramectin (DORA), and moxidectin (MOXI) in bovine plasma. A priority for sample preparation was the eradication of possible infectious diseases to avoid travel restrictions. The sample preparation was based on protein precipitation using 1% formic acid in acetonitrile, followed by Ostro^® 96-well plate pass-through sample clean-up. The simple and straightforward procedure, along with the short analysis time, makes the current method unique and suitable for a large set of sample analyses per day for PK studies. Chromatographic separation was performed using an Acquity UPLC HSS-T3 column, with 0.01% acetic acid in water and methanol, on an Acquity H-Class ultra-high performance liquid chromatograph (UHPLC) system. The MS/MS instrument was a Xevo TQ-S^® mass spectrometer, operating in the positive electrospray ionization mode and two multiple reaction monitoring (MRM) transitions were monitored per component. The MRM transitions of m/z 897.50 > 753.4 for IVER, m/z 921.70 > 777.40 for DORA and m/z 640.40 > 123.10 for MOXI were used for quantification. The method validation was performed using matrix-matched calibration curves in a concentration range of 1 to 500 ng/mL. Calibration curves fitted a quadratic regression model with 1/x2 weighting (r ≥ 0.998 and GoF ≤ 4.85%). Limits of quantification (LOQ) values of 1 ng/mL were obtained for all the analytes, while the limits of detection (LOD) were 0.02 ng/mL for IVER, 0.03 ng/mL for DORA, and 0.58 ng/mL for MOXI. The results of within-day (RSD < 6.50%) and between-day (RSD < 8.10%) precision and accuracies fell within acceptance ranges. No carry-over and no peak were detected in the UHPLC-MS/MS chromatogram of blank samples showing good specificity of the method. The applicability of the developed method was proved by an analysis of the field PK samples.     

LC–MS–MS Development and Validation for Simultaneous Quantitation of Metformin, Glimepiride and Pioglitazone in Human Plasma and Its Application to a Bioequivalence Study

A simple, precise and reproducible liquid chromatography–tandem mass spectrometry method has been developed and validated according to the Food and Drug Administration guidelines for the simultaneous quantitation of antidiabetic drugs metformin, glimiperide and pioglitazone in human plasma using glipizide as an internal standard. Quantitation was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring and positive ion mode. Inter-batch and intra-batch coefficient of variation across four validation runs for the quality control samples was less than 7%. The accuracy determined at quality control levels was within 92.81–105.13%. The method was applied to a bioequivalence study.     

LC–MS–MS Development and Validation for Simultaneous Quantitation of Metformin,Glimepiride and Pioglitazone in Human Plasma and Its Application to a Bioequivalence Study

A simple, precise and reproducible liquid chromatography–tandem mass spectrometry method has been developed and validated according to the Food and Drug Administration guidelines for the simultaneous quantitation of antidiabetic drugs metformin, glimiperide and pioglitazone in human plasma using glipizide as an internal standard. Quantitation was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring and positive ion mode. Inter-batch and intra-batch coefficient of variation across four validation runs for the quality control samples was less than 7%. The accuracy determined at quality control levels was within 92.81–105.13%. The method was applied to a bioequivalence study.

     

Development and Validation of Hptlc Method for Simultaneous Estimation of Propranolol Hydrochloride and Flunarizine Dihydrochloride in Combined Tablet Dosage Form

JPC – Journal of Planar Chromatography – Modern TLC - A simple, precise, and accurate high-performance thin-layer chromatography (HPTLC) method for the simultaneous determination of...     

HPLC Method for Determination of Rosiglitazone in Plasma

A fast and sensitive high performance liquid chromatography method for quantitative determination of rosiglitazone in human plasma has been developed. The extraction from plasma was performed using solid-phase extraction (SPE) on C4 silica (100 mg) disposable extraction cartridges (DEC). The separation of rosiglitazone and two metabolites was achieved on a Phenomenex® Synergi 4 µm MAX-RP (150 × 4.6 mm) column, protected by a guard column. The mobile phase was 0.01 M ammonium acetate, pH 7.0 - acetonitrile (65:35, v/v). (3S)-3-OH-quinidine was used as internal standard. The analytes were detected using fluorescence detection. The method was validated. The limit of quantitation was 1 ng mL⁻¹ and the detection limit was 0.25 ng mL⁻¹ for rosiglitazone in human plasma. The recovery was 90% for rosiglitazone. Linearity was observed over a range of 1-1000 ng mL⁻¹ (r²=0.9959). The intra- and inter-day precision (C.V.) did not exceed 8.7 %. Applicability of the method was demonstrated by a clinical pharmacokinetic study. A healthy volunteer received in two separate phases 4 mg and 8 mg rosiglitazone maleate as a single oral dose. Plasma concentrations were measured for 24 h in both phases.     

Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma

In the current work, a simple, economical, accurate, and precise HPLC method with UV detection was developed to quantify Favipiravir (FVIR) in spiked human plasma using acyclovir (ACVR) as an internal standard in the COVID-19 pandemic time. Both FVIR and ACVR were well separated and resolved on the C18 column using the mobile phase blend of methanol:acetonitrile:20 mM phosphate buffer (pH 3.1) in an isocratic mode flow rate of 1 mL/min with a proportion of 30:10:60 %, v/v/v. The detector wavelength was set at 242 nm. Maximum recovery of FVIR and ACVR from plasma was obtained with dichloromethane (DCM) as extracting solvent. The calibration curve was found to be linear in the range of 3.1–60.0 µg/mL with regression coefficient (r²) = 0.9976. However, with acceptable r², the calibration data’s heteroscedasticity was observed, which was further reduced using weighted linear regression with weighting factor 1/x. Finally, the method was validated concerning sensitivity, accuracy (Inter and Intraday’s % RE and RSD were 0.28, 0.65 and 1.00, 0.12 respectively), precision, recovery (89.99%, 89.09%, and 90.81% for LQC, MQC, and HQC, respectively), stability (% RSD for 30-day were 3.04 and 1.71 for LQC and HQC, respectively at −20 °C), and carry-over US-FDA guidance for Bioanalytical Method Validation for researchers in the COVID-19 pandemic crisis. Furthermore, there was no significant difference for selectivity when evaluated at LLOQ concentration of 3 µg/mL of FVIR and relative to the blank.     

Development and Validation of RP-HPLC Method for Simultaneous Estimation of Three-Component Tablet Formulation Containing Acetaminophen,Chlorzoxazone, and Aceclofenac

Abstract

The present work describes a simple reversed-phase high-performance liquid chromatographic method that has been developed and validated for simultaneous estimation of acetaminophen, chlorzoxazone, and aceclofenac in tablet dosage form. The estimation was carried out on an Luna C₁₈ (5 µm × 25 cm × 4.6 mm i.d.) column using a mixture of buffer, methanol, and acetonitrile in the ratio 215:130:155 with final pH of 6.5 as a mobile phase, at a flow rate of 1.5 ml/min. Ultraviolet (UV) detection was performed at 275 nm. Total run time was 10 min; these three drugs (acetaminophen, chlorzoxazone, and aceclofenac) were eluted at the retention times of 2.055, 5.096, and 7.605 min respectively. The method was validated for accuracy, precision, linearity, specificity, and sensitivity as per ICH norms.. From the validation study it was found that the method is specific, rapid, accurate, precise, and reproducible. Calibration curves were linear over the concentration ranges of 5–50 µg/ml for acetaminophen and chlorzoxazone, and 5–30 µg/ml for aceclofenac. All the validation study was found statistically significant because all the statistical parameters were within the acceptance range (i.e., COV % < 2.0 and S.D. < 1.0 for both accuracy and precision). The limit of detection (LOD) values were 16.2, 14.6, and 4.8 ng/ml, and LOQ values were 49.0, 46.5, and 14.5 ng/ml for acetaminophen, chlorzoxazone, and aceclofenac respectively. High recovery and low COV % revealed the reliability of the method for quantitative study of three drugs in Micronac-MR tablets. The method is a rapid and cost-effective quality-control tool for routine quantitative analysis of acetaminophen, chlorzoxazone, and aceclofenac in tablet dosage form.     

Rapid LC-UV Analysis of Iohexol in Canine Plasma for Glomerular Filtration Rate Determination

A rapid high-performance liquid chromatography UV method and a simple sample preparation for analyzing iohexol in canine plasma, for evaluating glomerular filtration rate (GFR) and intestinal permeability, were developed and validated. Trifluoroacetic acid (TFA) was used for protein precipitation and iohexol extraction from plasma, followed by vortex mixing and centrifugation. As an internal standard, 4-aminobenzoic acid (para-aminobenzoic acid, PABA) was added. The supernatant (5 μL) was injected into a Zorbax SB-C18 LC column maintained at 50 °C. The mobile phase of the LC method was a water–methanol gradient at pH 3.0 adjusted with TFA. Fast LC measurement was achieved by using a rapid-resolution LC technique. Total run time was 13 min, and UV wavelength was set at 246 nm. Precision of the method was 0.2–9.0%, depending on the iohexol concentration in plasma. Recovery of iohexol from plasma was over 90%, and recovery of the internal standard 99.1 ± 1.4%. The calibration curve was linear (r = 0.9997) over iohexol concentrations of 2.5–150 μg mL^?1 (n = 5). This method is fast, simple, reliable and applicable in clinical settings.